Engineered fusion protein aims to release LL-37 only at infection sites
The design targets the human cathelicidin peptide to dangerous bacteria, an approach pitched as an alternative to conventional antibiotics amid rising resistance.
PR
By Priya Raman · Science Reporter
Sep 25 20:02 ETSource: Bioengineer.org
The wire
- 01Researchers describe a fusion protein built to deliver LL-37, the only cathelicidin antimicrobial peptide found in humans, specifically where dangerous bacteria are present.
- 02LL-37 is one of the immune peptides readers track, and targeted delivery addresses the toxicity and stability problems that have limited systemic use.
- 03The report is a brief summary of early-stage work; no human data, organism panel or efficacy figures are given in the material at hand.
From the source
Read at bioengineer.orgEngineered Fusion Protein Delivers Antimicrobial Peptides Only Where Dangerous Bacteria Strike
Antimicrobial resistance remains one of the most pressing threats to modern medicine, and researchers around the world are racing to find alternatives to conventional antibiotics. One of the most promising candidates to emerge in recent decades is LL-37, the only cathelicidin antimicrobial peptide found in humans. This
